At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
Phytosterols & placebodietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study of Phytosterols for Insulin-like Growth Factor-1 and Endothelial Progenitor Cell Levels in Patients With Nonalcoholic Fatty Liver Disease
In Brief
A clinical study evaluating Phytosterols & placebo for Non-alcoholic Fatty Liver Disease. Completed, enrolled 40 participants across 1 site.
Detailed Summary
Phytosterols are plant sterols . Phytosterols have anti-inflammation effect. Investigators have a hypothesis: phytosterols reduce oxidative stress , enhance Insulin-like growth factor-1(IGF-1) and endothelial progenitor cells(EPCs). Therefore, phytosterols has novel role in cardiovascular protection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Fatty Liver Disease
CountriesTaiwan
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2012
Primary CompletionDec 2012
First PostedJun 2013
Study CompletionJul 2013
TodayJul 2026
First PostedJun 12, 2013
Enrollment StartOct 1, 2012
Primary CompletionDec 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.1 years ago
Interventions
Phytosterols & placebodietary
Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first